Thought Leadership

Latest Report

Obesity matters for drug developers

Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%.  The R&D pipeline is filling up as more and more companies try to grab a slice of this…

Report library

JP Morgan Healthcare Conference 2023

The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started…

Evaluate Vantage 2023 Preview Infographic

The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already…

ASH 2022

As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering…

Evaluate Vantage 2023 Preview

After a tough year for many in biopharma, what’s the outlook for 2023? Evaluate Vantage’s preview sets out the projects waiting in the wings that could drive some…

ASH 2022 Preview

The 2022 ASH Annual Meeting is due to take place on December 10-13 in New Orleans, Louisiana. Get yourself prepared with Evaluate Vantage's preview of the…

Thumbnail

How to spot blockbuster potential?

In 2021, the pharma industry invested over $600 billion in R&D, M&A and licensing in search of the next life-changing and market-leading products. With a patent…

Thumbnail

Q3 Round Up: Alive but not kicking report

What happened in Q3? Did the glimmers of light we saw at the start of the quarter really come to anything or were they a false dawn? In this eBook, we investigate whether…